{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:51:38Z","timestamp":1778226698948,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Castration resistance is a lethal form of treatment failure of prostate cancer (PCa) and is associated with ligand-independent activation of the androgen receptor (AR). It is only partially understood how the AR mediates survival and castration-resistant growth of PCa upon androgen deprivation. We investigated integrative genomics using a patient-derived xenograft model recapitulating acquired, AR-dependent castration-resistant PCa (CRPC). Sequencing of chromatin immunoprecipitation using an anti-AR antibody (AR-ChIP seq) revealed distinct profiles of AR binding site (ARBS) in androgen-dependent and castration-resistant xenograft tumors compared with those previously reported based on human PCa cells or tumor tissues. An integrative genetic analysis identified several AR-target genes associated with CRPC progression including OPRK1, which harbors ARBS and was upregulated upon androgen deprivation. Loss of function of OPRK1 retarded the acquisition of castration resistance and inhibited castration-resistant growth of PCa both in vitro and in vivo. Immunohistochemical analysis showed that expression of OPRK1, a G protein-coupled receptor, was upregulated in human prostate cancer tissues after preoperative androgen derivation or CRPC progression. These data suggest that OPRK1 is involved in post-castration survival and cellular adaptation process toward castration-resistant progression of PCa, accelerating the clinical implementation of ORPK1-targeting therapy in the management of this lethal disease.<\/jats:p>","DOI":"10.1038\/s42003-022-03227-w","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:21:23Z","timestamp":1648808483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1"],"prefix":"10.1038","volume":"5","author":[{"given":"Yuki","family":"Makino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-1531","authenticated-orcid":false,"given":"J. B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-7898","authenticated-orcid":false,"given":"Toshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-7506","authenticated-orcid":false,"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-2816","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"3227_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1200\/EDBK_200967","volume":"38","author":"AW Hahn","year":"2018","unstructured":"Hahn, A. W., Higano, C. S., Taplin, M. E., Ryan, C. J. & Agarwal, N. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am. Soc. Clin. Oncol. Educ. Book 38, 363\u2013371 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo, M. Y., Rathkopf, D. E. & Kantoff, P. Treatment of advanced prostate cancer. Annu. Rev. Med. 70, 479\u2013499 (2019).","journal-title":"Annu. Rev. Med."},{"key":"3227_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/me.2009-0326","volume":"24","author":"T Kobayashi","year":"2010","unstructured":"Kobayashi, T. et al. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. Mol. Endocrinol. 24, 722\u2013734 (2010).","journal-title":"Mol. Endocrinol."},{"key":"3227_CR5","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/S0959-8049(11)70163-0","volume":"47","author":"B Tombal","year":"2011","unstructured":"Tombal, B. What is the pathophysiology of a hormone-resistant prostate tumour? Eur. J. Cancer 47, S179\u2013S188 (2011).","journal-title":"Eur. J. Cancer"},{"key":"3227_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575\u2013586 (2011).","journal-title":"Cancer Cell"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-13-0359","volume":"73","author":"H Matsumoto","year":"2013","unstructured":"Matsumoto, H. et al. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability. Cancer Res. 73, 5206\u20135217 (2013).","journal-title":"Cancer Res."},{"key":"3227_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"3227_CR9","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","volume":"23","author":"HI Scher","year":"2005","unstructured":"Scher, H. I. & Sawyers, C. L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253\u20138261 (2005).","journal-title":"J. Clin. Oncol."},{"key":"3227_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","volume":"30","author":"PS Nelson","year":"2012","unstructured":"Nelson, P. S. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J. Clin. Oncol. 30, 644\u2013646 (2012).","journal-title":"J. Clin. Oncol."},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"15615","DOI":"10.3390\/ijms140815615","volume":"14","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi, T., Inoue, T., Kamba, T. & Ogawa, O. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J. Mol. Sci. 14, 15615\u201315635 (2013).","journal-title":"Int J. Mol. Sci."},{"key":"3227_CR12","doi-asserted-by":"publisher","unstructured":"Kita, Y. et al. Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: opportunities and challenges. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers10100345 (2018).","DOI":"10.3390\/cancers10100345"},{"key":"3227_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","volume":"138","author":"Q Wang","year":"2009","unstructured":"Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245\u2013256 (2009).","journal-title":"Cell"},{"key":"3227_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/iju.12146","volume":"20","author":"K Takayama","year":"2013","unstructured":"Takayama, K. & Inoue, S. Transcriptional network of androgen receptor in prostate cancer progression. Int J. Urol. 20, 756\u2013768 (2013).","journal-title":"Int J. Urol."},{"key":"3227_CR15","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1210\/me.2006-0033","volume":"20","author":"T Inoue","year":"2006","unstructured":"Inoue, T. et al. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol. Endocrinol. 20, 3053\u20133069 (2006).","journal-title":"Mol. Endocrinol."},{"key":"3227_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/0008-5472.CAN-09-2984","volume":"70","author":"N Terada","year":"2010","unstructured":"Terada, N. et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res. 70, 1606\u20131615 (2010).","journal-title":"Cancer Res."},{"key":"3227_CR17","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305\u20132313 (2009).","journal-title":"Cancer Res."},{"key":"3227_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16\u201322 (2009).","journal-title":"Cancer Res."},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai, C. et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71, 6503\u20136513 (2011).","journal-title":"Cancer Res."},{"key":"3227_CR20","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1158\/1078-0432.CCR-08-1350","volume":"15","author":"E Ashihara","year":"2009","unstructured":"Ashihara, E. et al. Beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin. Cancer Res. 15, 2731\u20132738 (2009).","journal-title":"Clin. Cancer Res."},{"key":"3227_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"3227_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","volume":"23","author":"NL Sharma","year":"2013","unstructured":"Sharma, N. L. et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23, 35\u201347 (2013).","journal-title":"Cancer Cell"},{"key":"3227_CR23","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","volume":"72","author":"R Hu","year":"2012","unstructured":"Hu, R. et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457\u20133462 (2012).","journal-title":"Cancer Res."},{"key":"3227_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research, N.","year":"2015","unstructured":"Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"3227_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369\u2013378 (2016).","journal-title":"Nat. Med."},{"key":"3227_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243 (2012).","journal-title":"Nature"},{"key":"3227_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","volume":"20","author":"C Cai","year":"2011","unstructured":"Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457\u2013471 (2011).","journal-title":"Cancer Cell"},{"key":"3227_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"3227_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-6-r41","volume":"4","author":"P Broberg","year":"2003","unstructured":"Broberg, P. Statistical methods for ranking differentially expressed genes. Genome Biol. 4, R41 (2003).","journal-title":"Genome Biol."},{"key":"3227_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.6120570","volume":"215","author":"C Chavkin","year":"1982","unstructured":"Chavkin, C., James, I. F. & Goldstein, A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215, 413\u2013415 (1982).","journal-title":"Science"},{"key":"3227_CR31","first-page":"567","volume":"48","author":"BN Dhawan","year":"1996","unstructured":"Dhawan, B. N. et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharm. Rev. 48, 567\u2013592 (1996).","journal-title":"Pharm. Rev."},{"key":"3227_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.celrep.2016.09.064","volume":"17","author":"S Gao","year":"2016","unstructured":"Gao, S. et al. Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein. Cell Rep. 17, 966\u2013976 (2016).","journal-title":"Cell Rep."},{"key":"3227_CR33","first-page":"164","volume":"6","author":"H Yamashita","year":"2018","unstructured":"Yamashita, H., Shuman, L., Warrick, J. I., Raman, J. D. & Degraff, D. J. Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. Am. J. Clin. Exp. Urol. 6, 164\u2013171 (2018).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"3227_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato, L. et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell 35, 401\u2013413 e6 (2019).","journal-title":"Cancer Cell"},{"key":"3227_CR35","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1158\/0008-5472.CAN-08-1083","volume":"68","author":"HS Jeon","year":"2008","unstructured":"Jeon, H. S. et al. SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res. 68, 9686\u20139692 (2008).","journal-title":"Cancer Res."},{"key":"3227_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep24968","volume":"6","author":"M de Boeck","year":"2016","unstructured":"de Boeck, M. et al. Smad6 determines BMP-regulated invasive behaviour of breast cancer cells in a zebrafish xenograft model. Sci. Rep. 6, 24968 (2016).","journal-title":"Sci. Rep."},{"key":"3227_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/pros.22788","volume":"74","author":"J Sharma","year":"2014","unstructured":"Sharma, J. et al. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 74, 820\u2013828 (2014).","journal-title":"Prostate"},{"key":"3227_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1517\/14728222.2014.934814","volume":"18","author":"M Garg","year":"2014","unstructured":"Garg, M., Braunstein, G. & Koeffler, H. P. LAMC2 as a therapeutic target for cancers. Expert Opin. Ther. Targets 18, 979\u2013982 (2014).","journal-title":"Expert Opin. Ther. Targets"},{"key":"3227_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/1541-7786.MCR-19-0595","volume":"18","author":"JP Maynard","year":"2020","unstructured":"Maynard, J. P. et al. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol. Cancer Res. 18, 153\u2013165 (2020).","journal-title":"Mol. Cancer Res."},{"key":"3227_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ucl.2017.07.008","volume":"44","author":"S Damodaran","year":"2017","unstructured":"Damodaran, S., Kyriakopoulos, C. E. & Jarrard, D. F. Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol. Clin. North Am. 44, 611\u2013621 (2017).","journal-title":"Urol. Clin. North Am."},{"key":"3227_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara, N. et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of Phase 3 Latitude study. Eur. Urol. 77, 494\u2013500 (2020).","journal-title":"Eur. Urol."},{"key":"3227_CR42","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain, M. et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 27, 2450\u20132456 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3227_CR43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/JU.0000000000000117","volume":"201","author":"S Damodaran","year":"2019","unstructured":"Damodaran, S., Lang, J. M. & Jarrard, D. F. Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches. J. Urol. 201, 876\u2013885 (2019).","journal-title":"J. Urol."},{"key":"3227_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474\u2013489 e6 (2017).","journal-title":"Cancer Cell"},{"key":"3227_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su, W. et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell 36, 139\u2013155 e10 (2019).","journal-title":"Cancer Cell"},{"key":"3227_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471250953.bi1112s47","volume":"47","author":"AR Quinlan","year":"2014","unstructured":"Quinlan, A. R. BEDTools: The swiss-army tool for genome feature analysis. Curr. Protoc. Bioinforma. 47, 1\u201334 (2014). 11 12.","journal-title":"Curr. Protoc. Bioinforma."},{"key":"3227_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2016.02.027","volume":"141","author":"R Murakami","year":"2016","unstructured":"Murakami, R. et al. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol. Oncol. 141, 49\u201356 (2016).","journal-title":"Gynecol. Oncol."},{"key":"3227_CR48","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","volume":"186","author":"R Murakami","year":"2016","unstructured":"Murakami, R. et al. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am. J. Pathol. 186, 1103\u20131113 (2016).","journal-title":"Am. J. Pathol."},{"key":"3227_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000449323","volume":"44","author":"N Kushida","year":"2016","unstructured":"Kushida, N. et al. Hypoxia-inducible factor-1alpha activates the transforming growth factor-beta\/SMAD3 pathway in kidney tubular epithelial cells. Am. J. Nephrol. 44, 276\u2013285 (2016).","journal-title":"Am. J. Nephrol."}],"updated-by":[{"DOI":"10.1038\/s42003-022-03707-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000}}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03227-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03227-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03227-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:26:32Z","timestamp":1669364792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03227-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03227-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s42003-022-03707-z","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s42003-022-03707-z","URL":"https:\/\/doi.org\/10.1038\/s42003-022-03707-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}